LUGANO, Switzerland, September 9 As part of the HelsinnGroup's development strategy, William Mann, PhD, has been appointed as newCEO in the American subsidiary, Helsinn Therapeutics (U.S.) Inc. WilliamMann, PhD, was already Chief Operating Officer of the recently acquiredHelsinn Therapeutics, and has held leadership positions in a Swissmultinational with positions in Business Development and in Research.
Moreover, Helsinn announces that Mr. William Brown has been hired as VicePresident Commercial Operations USA, to build a Helsinn Therapeutics directsales structure in the United States. Mr. Brown has experience inmultinational groups and in the management of Supportive Care, havingpreviously managed the product Aloxi in MGI Pharma.
Dr. Riccardo Braglia, the Helsinn group's CEO said, "Helsinn wishes toimplement a new group growth strategy in the United States, placing more andmore importance on the project development and acquisition of new businessexpertise. The appointments of William Mann and William Brown will allow usto consolidate Helsinn's US business, the projects currently in developmentin cancer supportive care and in gastrointestinal areas and will lay thefoundations for further development in North America also from a commercialpoint of view."
About Helsinn Group
Helsinn is a privately owned pharmaceutical group with headquarters inLugano, Switzerland, and subsidiaries in USA and Ireland. Helsinn's uniquebusiness model is focused on the licensing of pharmaceuticals and medicaldevices in therapeutic niche areas. The Group in-licenses early stage newchemical entities, completes their development from the performance ofpre-clinical/clinical studies and Chemistry, Manufacturing and Control (CMC)development, to the filing for and attainment of their market approvalworldwide.
Helsinn's products are sold directly, through the Group subsidiaries, oreventually out-licensed to its network of local marketing and commercialpartners, selected for their deep in-market knowledge and know-how, andassisted and supported with a full range of product and scientific managementservices, including commercial, regulatory, financial, legal and medicalmarketing advice.
The active pharmaceutical ingredients and the finished dosage forms aremanufactured at Helsinn's cGMP facilities in Switzerland and Ireland, andsupplied worldwide to its customers. Helsinn is the worldwide licensor ofpalonosetron, a second generation 5-HT3 receptor antagonist, for theprevention of chemotherapy-induced nausea and vomiting (CINV) and ofpost-operative nausea and vomiting (PONV) in patients with cancer, and of theoriginal nimesulide, a non-steroidal anti-inflammatory drug (NSAID)distributed in more than 50 countries worldwide.
Helsinn, with a workforce of around 450 employees in Switzerland, Irelandand USA, reported a 2008 turnover of over CHF 280.3 million (about EUR 178million), covering 75 countries worldwide, with over 20% of this turnoverinvested in R&D.
For more information about Helsinn Group, please visit the website:http://www.helsinn.comContact person at Helsinn Healthcare SA: Paola Bonvicini Head of Communication & Press Office Tel.: +41-91-985-21-21 E-Mail: [email protected]
SOURCE Helsinn Healthcare SA